Postnatal steroids in the treatment of bronchopulmonary dysplasia

Abstract

Bronchopulmonary dysplasia (BPD) is an adverse outcome of prematurity which affects approximately 40% of newborns with a gestational age (GA) <29 weeks. This review article describes the current consensus over the use of postnatal steroids in the treatment of BPD, providing an insight into historical clues, optimal patient selection, timing of the therapy, alternative routes of administration, and therapeutic strategies.